semaglutide development A new era for oral peptides: SNAC and the of oral for the treatment of type 2 diabetes | Reviews in Endocrine and Metabolic Disorders Emerging Trends in the Development

Animal studies suggest GLP-1 agonists reduce alcohol self-administration, and growing anecdotal reports from patients describe decreased drinking urges while on semaglutide

But Novo Nordisk says NAION is not an adverse drug reaction for semaglutide

GLP-1: : GLP-1 (15%), CaffXtend (5%), , , , : GLP1 (15%) : , , , ,

Weeks 1-6 Loading Phase Topical: twice-daily application over treatment zones Injection: 250500 g sub-Q, 35 weekly Weekly RN check-ins to track skin metrics, pain scores, and hair density photos

However, it is important to understand that this was a population at very high risk of renal and cardiovascular events, and the authors warn that the outcomes in this study may not be generalisable to other populations